Dynavax Technologies Stock Price, News & Analysis (NASDAQ:DVAX)

$17.23 +0.18 (+1.06 %)
(As of 02/20/2018 04:00 PM ET)
Previous Close$17.23
Today's Range$17.05 - $17.40
52-Week Range$3.90 - $24.45
Volume714,100 shs
Average Volume1.43 million shs
Market Capitalization$1.03 billion
P/E Ratio-8.79
Dividend YieldN/A
Beta1.08

About Dynavax Technologies (NASDAQ:DVAX)

Dynavax Technologies logoDynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, SD-101, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. SD-101 is an investigational TLR9 agonist designed to elicit a potent and focused immune response to cancer. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.

Receive DVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:DVAX
CUSIP26815810
Phone+1-510-8485100

Debt

Debt-to-Equity RatioN/A
Current Ratio15.30%
Quick Ratio15.30%

Price-To-Earnings

Trailing P/E Ratio-8.79081632653061
Forward P/E Ratio-10.02
P/E GrowthN/A

Sales & Book Value

Annual Sales$11.04 million
Price / Sales94.58
Cash FlowN/A
Price / CashN/A
Book Value$2.32 per share
Price / Book7.43

Profitability

Trailing EPS($1.96)
Net Income$-112,440,000.00
Net Margins-1,177.60%
Return on Equity-65.97%
Return on Assets-59.47%

Miscellaneous

Employees251
Outstanding Shares60,600,000

Dynavax Technologies (NASDAQ:DVAX) Frequently Asked Questions

What is Dynavax Technologies' stock symbol?

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies Co. (NASDAQ:DVAX) issued its quarterly earnings results on Friday, November, 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.53) by $0.15. The biopharmaceutical company earned $0.05 million during the quarter, compared to the consensus estimate of $0.28 million. Dynavax Technologies had a negative net margin of 1,177.60% and a negative return on equity of 65.97%. The firm's quarterly revenue was down 68.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.90) EPS. View Dynavax Technologies' Earnings History.

When will Dynavax Technologies make its next earnings announcement?

Dynavax Technologies is scheduled to release their next quarterly earnings announcement on Monday, March, 12th 2018. View Earnings Estimates for Dynavax Technologies.

Where is Dynavax Technologies' stock going? Where will Dynavax Technologies' stock price be in 2018?

5 brokers have issued 1-year target prices for Dynavax Technologies' shares. Their predictions range from $25.00 to $30.00. On average, they anticipate Dynavax Technologies' share price to reach $27.60 in the next year. View Analyst Ratings for Dynavax Technologies.

What are Wall Street analysts saying about Dynavax Technologies stock?

Here are some recent quotes from research analysts about Dynavax Technologies stock:

  • 1. According to Zacks Investment Research, "Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. " (1/10/2018)
  • 2. Cantor Fitzgerald analysts commented, "Launch in 1Q18. Dynavax anticipates launching the product in 1Q18 and previously noted drug supply of over 250,000 vials of product available by the time of launch, with an additional 750,000 vials worth of raw material. In 2H18, Dynavax expects its Dusseldorf plant to manufacture drug supply. We estimate the current supply will support commercialization for over two years, providing ample runway to produce additional supply." (11/9/2017)
  • 3. Cowen Inc analysts commented, "Dynavax reported a Q3 net loss of $22.1MM and ended the quarter with $192MM in." (11/3/2017)

Who are some of Dynavax Technologies' key competitors?

Who are Dynavax Technologies' key executives?

Dynavax Technologies' management team includes the folowing people:

  • Arnold L. Oronsky Ph.D., Independent Chairman of the Board (Age 77)
  • Eddie Gray, Chief Executive Officer, Director (Age 58)
  • Michael S. Ostrach, Chief Financial Officer, Senior Vice President, Chief Business Officer (Age 65)
  • Robert L. Coffman Ph.D., Senior Vice President, Chief Scientific Officer (Age 70)
  • David F. Novack, Senior Vice President - Operations and Quality (Age 55)
  • Robert Janssen M.D., Chief Medical Officer, Vice President - Clinical Development and Regulatory Affairs (Age 63)
  • Laura A. Brege, Independent Director (Age 59)
  • Francis R. Cano Ph.D., Independent Director (Age 70)
  • Dennis A. Carson M.D., Independent Director (Age 70)
  • Daniel L. Kisner M.D., Independent Director (Age 70)

Who owns Dynavax Technologies stock?

Dynavax Technologies' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.39%), Senvest Management LLC (2.54%), Deutsche Bank AG (2.35%), Franklin Resources Inc. (1.75%), C WorldWide Group Holding A S (1.27%) and Clearbridge LLC (0.91%). Company insiders that own Dynavax Technologies stock include David Louis Johnson, Eddie Gray, Robert Coffman and Robert Janssen. View Institutional Ownership Trends for Dynavax Technologies.

Who sold Dynavax Technologies stock? Who is selling Dynavax Technologies stock?

Dynavax Technologies' stock was sold by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, UBS Asset Management Americas Inc., Goldman Sachs Group Inc., Candriam Luxembourg S.C.A., Vident Investment Advisory LLC, First Republic Investment Management Inc., Bank of New York Mellon Corp and Alliancebernstein L.P.. Company insiders that have sold Dynavax Technologies company stock in the last year include David Louis Johnson and Robert Coffman. View Insider Buying and Selling for Dynavax Technologies.

Who bought Dynavax Technologies stock? Who is buying Dynavax Technologies stock?

Dynavax Technologies' stock was acquired by a variety of institutional investors in the last quarter, including Clearbridge LLC, Senvest Management LLC, Bain Capital Public Equity Management LLC, First Trust Advisors LP, Millennium Management LLC, Franklin Resources Inc., Creative Planning and Alps Advisors Inc.. Company insiders that have bought Dynavax Technologies stock in the last two years include Eddie Gray and Robert Janssen. View Insider Buying and Selling for Dynavax Technologies.

How do I buy Dynavax Technologies stock?

Shares of Dynavax Technologies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dynavax Technologies' stock price today?

One share of Dynavax Technologies stock can currently be purchased for approximately $17.23.

How big of a company is Dynavax Technologies?

Dynavax Technologies has a market capitalization of $1.03 billion and generates $11.04 million in revenue each year. The biopharmaceutical company earns $-112,440,000.00 in net income (profit) each year or ($1.96) on an earnings per share basis. Dynavax Technologies employs 251 workers across the globe.

How can I contact Dynavax Technologies?

Dynavax Technologies' mailing address is 2929 7th St Ste 100, BERKELEY, CA 94710-2753, United States. The biopharmaceutical company can be reached via phone at +1-510-8485100 or via email at [email protected]


MarketBeat Community Rating for Dynavax Technologies (DVAX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  218 (Vote Outperform)
Underperform Votes:  208 (Vote Underperform)
Total Votes:  426
MarketBeat's community ratings are surveys of what our community members think about Dynavax Technologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Dynavax Technologies (NASDAQ:DVAX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.803.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $27.60$28.00$28.00$25.80
Price Target Upside: 60.47% upside39.65% upside39.65% upside50.01% upside

Dynavax Technologies (NASDAQ:DVAX) Consensus Price Target History

Price Target History for Dynavax Technologies (NASDAQ:DVAX)

Dynavax Technologies (NASDAQ:DVAX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/14/2018JPMorgan Chase & Co.DowngradeOverweight -> Neutral$31.00 -> $25.00MediumView Rating Details
11/9/2017Cantor FitzgeraldBoost Price TargetOverweight$24.00 -> $25.00N/AView Rating Details
11/3/2017CowenReiterated RatingBuy$30.00N/AView Rating Details
9/25/2017Royal Bank of CanadaReiterated RatingOutperform -> Outperform$26.00 -> $28.00HighView Rating Details
8/9/2017William BlairReiterated RatingOutperform$30.00HighView Rating Details
9/2/2016S&P Equity ResearchBoost Price Target$11.28 -> $16.01N/AView Rating Details
(Data available from 2/20/2016 forward)

Earnings

Dynavax Technologies (NASDAQ:DVAX) Earnings History and Estimates Chart

Earnings by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Dynavax Technologies (NASDAQ DVAX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/12/2018($0.11)N/AView Earnings Details
11/3/2017Q3 2017($0.53)($0.38)$0.28 million$0.05 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.50)($0.41)$0.15 million$0.11 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.60)($0.60)$0.75 million$0.15 millionViewN/AView Earnings Details
3/13/2017Q4 2016($0.85)($0.56)$2.90 million$7.30 millionViewN/AView Earnings Details
11/7/2016Q3($0.75)($0.90)$2.44 million$0.20 millionViewN/AView Earnings Details
8/5/2016Q2($0.68)($0.75)$1.58 million$2.65 millionViewN/AView Earnings Details
5/9/2016Q1($0.63)($0.70)$627.00 million$942.00 millionViewN/AView Earnings Details
3/8/2016Q4($0.75)($0.70)$1.15 million$0.69 millionViewN/AView Earnings Details
11/5/2015Q3($0.78)($0.82)$1.65 million$1.20 millionViewN/AView Earnings Details
8/7/2015Q2($1.00)($0.80)$3.05 million$1.55 millionViewN/AView Earnings Details
5/7/2015Q1 2015($0.95)($0.97)$1.26 million$0.63 millionViewN/AView Earnings Details
3/5/2015Q4 2014($1.06)($0.85)$2.15 million$2.28 millionViewN/AView Earnings Details
11/5/2014Q314($0.09)($0.11)$2.50 million$2.21 millionViewN/AView Earnings Details
8/7/2014Q214($0.06)($0.09)$2.26 million$3.05 millionViewN/AView Earnings Details
5/5/2014Q1 2014($0.06)($0.05)$4.22 million$3.50 millionViewN/AView Earnings Details
3/10/2014Q413($0.07)($0.09)$1.56 million$2.80 millionViewN/AView Earnings Details
11/7/2013Q313($0.10)($0.09)$1.83 million$2.93 millionViewN/AView Earnings Details
7/29/2013Q2 2013($0.10)($0.09)$2.91 million$3.40 millionViewN/AView Earnings Details
5/6/2013Q113($0.11)($0.11)$2.40 million$2.10 millionViewN/AView Earnings Details
3/1/2013Q4 2012($0.11)$11.40 million$1.80 millionViewN/AView Earnings Details
11/1/2012Q312($0.08)($0.10)$5.00 million$2.90 millionViewN/AView Earnings Details
8/1/2012Q2 2012($1.00)($0.90)ViewN/AView Earnings Details
4/27/2012Q1 2012($0.80)($1.06)ViewN/AView Earnings Details
3/6/2012Q4 2011($0.70)($0.30)ViewN/AView Earnings Details
10/27/2011Q3 2011($1.30)($1.23)ViewN/AView Earnings Details
7/20/2011Q2 2011($1.10)($0.90)ViewN/AView Earnings Details
5/5/2011Q1 2011($1.50)($1.58)ViewN/AView Earnings Details
3/8/2011Q4 2010($1.40)($1.43)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.30)($0.55)ViewN/AView Earnings Details
7/30/2010Q2 2010($1.30)($3.41)ViewN/AView Earnings Details
5/6/2010Q1 2010($1.69)ViewN/AView Earnings Details
3/16/2010Q4 2009($7.31)ViewN/AView Earnings Details
10/22/2009Q3 2009($2.40)($2.37)ViewN/AView Earnings Details
8/4/2009Q2 2009$0.40$1.03ViewN/AView Earnings Details
4/28/2009Q1 2009($0.20)$1.28ViewN/AView Earnings Details
3/2/2009Q4 2008($0.60)$0.78ViewN/AView Earnings Details
11/3/2008Q3 2008($1.10)($1.36)ViewN/AView Earnings Details
8/5/2008Q2 2008($2.40)($1.53)ViewN/AView Earnings Details
4/29/2008Q1 2008($2.30)($3.12)ViewN/AView Earnings Details
2/19/2008Q4 2007($3.40)($3.04)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Dynavax Technologies (NASDAQ:DVAX) Earnings Estimates

2018 EPS Consensus Estimate: ($1.51)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.43)($0.43)($0.43)
Q2 20181($0.41)($0.41)($0.41)
Q3 20181($0.38)($0.38)($0.38)
Q4 20181($0.29)($0.29)($0.29)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Dynavax Technologies (NASDAQ:DVAX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Dynavax Technologies (NASDAQ DVAX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.90%
Institutional Ownership Percentage: 65.81%
Insider Trades by Quarter for Dynavax Technologies (NASDAQ:DVAX)
Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Dynavax Technologies (NASDAQ DVAX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/4/2018David Louis JohnsonVPSell3,092$18.60$57,511.207,780View SEC Filing  
12/13/2017Robert CoffmanInsiderSell7,500$18.90$141,750.00View SEC Filing  
1/24/2017Robert JanssenVPBuy6,000$4.04$24,240.0012,048View SEC Filing  
6/28/2016Robert JanssenVPBuy1,452$13.68$19,863.366,048View SEC Filing  
5/20/2016Eddie GrayCEOBuy2,750$15.57$42,817.505,050View SEC Filing  
5/12/2016Robert JanssenVPBuy1,000$15.12$15,120.001,000View SEC Filing  
8/14/2014Eddie GrayCEOBuy25,000$1.49$37,250.00View SEC Filing  
10/30/2013Peggy V PhillipsDirectorBuy93,023$1.08$100,464.84View SEC Filing  
9/14/2012Jennifer LewVPSell18,750$4.53$84,937.50View SEC Filing  
9/13/2012Robert CoffmanVPSell8,000$4.52$36,160.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Dynavax Technologies (NASDAQ DVAX) News Headlines

Source:
DateHeadline
Dynavax Secures $175 Million in Non-Dilutive Debt FinancingDynavax Secures $175 Million in Non-Dilutive Debt Financing
finance.yahoo.com - February 20 at 8:46 AM
Dynavax Technologies Co. (DVAX) Receives Consensus Rating of "Hold" from AnalystsDynavax Technologies Co. (DVAX) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - February 16 at 1:36 AM
Dynavax Technologies (DVAX) Rating Lowered to Neutral at JPMorgan Chase & Co.Dynavax Technologies (DVAX) Rating Lowered to Neutral at JPMorgan Chase & Co.
www.americanbankingnews.com - February 14 at 10:40 PM
JPMorgan Downgrades Dynavax Technologies (DVAX) to Neutral - StreetInsider.comJPMorgan Downgrades Dynavax Technologies (DVAX) to Neutral - StreetInsider.com
www.streetinsider.com - February 14 at 3:27 PM
Dynavax to Present at the RBC Capital Markets Global Healthcare ConferenceDynavax to Present at the RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - February 14 at 3:27 PM
Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire (press release)Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire (press release)
globenewswire.com - February 3 at 6:40 AM
Watch These February Biotech Catalysts - Seeking AlphaWatch These February Biotech Catalysts - Seeking Alpha
seekingalpha.com - January 31 at 3:25 PM
Commit To Purchase Dynavax Technologies Corp At $10, Earn 13.2% Annualized Using Options - NasdaqCommit To Purchase Dynavax Technologies Corp At $10, Earn 13.2% Annualized Using Options - Nasdaq
www.nasdaq.com - January 24 at 3:28 PM
Dynavax Technologies Co. (DVAX) Receives Average Recommendation of "Hold" from AnalystsDynavax Technologies Co. (DVAX) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 22 at 1:40 AM
BidaskClub Downgrades Dynavax Technologies (DVAX) to Strong SellBidaskClub Downgrades Dynavax Technologies (DVAX) to Strong Sell
www.americanbankingnews.com - January 21 at 3:34 PM
Traders Buy High Volume of Put Options on Dynavax Technologies (DVAX)Traders Buy High Volume of Put Options on Dynavax Technologies (DVAX)
www.americanbankingnews.com - January 11 at 1:52 AM
Dynavax Technologies (DVAX) Downgraded to Sell at Zacks Investment ResearchDynavax Technologies (DVAX) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - January 11 at 12:52 AM
William Blair Comments on Dynavax Technologies Co.s FY2017 Earnings (DVAX)William Blair Comments on Dynavax Technologies Co.'s FY2017 Earnings (DVAX)
www.americanbankingnews.com - January 10 at 6:56 AM
Dynavax Technologies Corporation (DVAX) Announces the Launch of HEPLISAV-B in the USDynavax Technologies Corporation (DVAX) Announces the Launch of HEPLISAV-B in the US
finance.yahoo.com - January 8 at 5:26 PM
$37.77 Million in Sales Expected for Dynavax Technologies Co. (DVAX) This Quarter$37.77 Million in Sales Expected for Dynavax Technologies Co. (DVAX) This Quarter
www.americanbankingnews.com - January 8 at 4:02 PM
Dynavax Announces HEPLISAV-B™ is Now Available in the United States for the Prevention of Hepatitis B in AdultsDynavax Announces HEPLISAV-B™ is Now Available in the United States for the Prevention of Hepatitis B in Adults
finance.yahoo.com - January 8 at 9:52 AM
Want To Invest In Dynavax Technologies Corporation (NASDAQ:DVAX)? Here’s How It Performed LatelyWant To Invest In Dynavax Technologies Corporation (NASDAQ:DVAX)? Here’s How It Performed Lately
finance.yahoo.com - January 8 at 9:52 AM
1 Reason Dynavax Technologies Corporation Stock Soared in 20171 Reason Dynavax Technologies Corporation Stock Soared in 2017
www.fool.com - January 8 at 8:26 AM
David Louis Johnson Sells 3,092 Shares of Dynavax Technologies Co. (DVAX) StockDavid Louis Johnson Sells 3,092 Shares of Dynavax Technologies Co. (DVAX) Stock
www.americanbankingnews.com - January 5 at 6:50 PM
Dynavax Technologies Corp. – Value Analysis (NASDAQ:DVAX) : December 29, 2017Dynavax Technologies Corp. – Value Analysis (NASDAQ:DVAX) : December 29, 2017
finance.yahoo.com - December 29 at 5:15 PM
Dynavax Technologies Corp. breached its 50 day moving average in a Bearish Manner : DVAX-US : December 28, 2017Dynavax Technologies Corp. breached its 50 day moving average in a Bearish Manner : DVAX-US : December 28, 2017
finance.yahoo.com - December 28 at 1:55 PM
Dynavax Technologies Co. (DVAX) Given Consensus Recommendation of "Buy" by BrokeragesDynavax Technologies Co. (DVAX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - December 28 at 2:12 AM
3 Growth Stocks to Own in 20183 Growth Stocks to Own in 2018
finance.yahoo.com - December 26 at 8:44 AM
What Does 2018 Have In Store For Dynavax? - Seeking AlphaWhat Does 2018 Have In Store For Dynavax? - Seeking Alpha
seekingalpha.com - December 23 at 7:44 PM
Zacks: Brokerages Anticipate Dynavax Technologies Co. (DVAX) Will Post Quarterly Sales of $37.77 MillionZacks: Brokerages Anticipate Dynavax Technologies Co. (DVAX) Will Post Quarterly Sales of $37.77 Million
www.americanbankingnews.com - December 23 at 12:02 PM
 Brokerages Expect Dynavax Technologies Co. (DVAX) to Announce $0.30 Earnings Per Share Brokerages Expect Dynavax Technologies Co. (DVAX) to Announce $0.30 Earnings Per Share
www.americanbankingnews.com - December 21 at 1:14 AM
Insider Selling: Dynavax Technologies Corporation (DVAX) Insider Sells 7,500 Shares of StockInsider Selling: Dynavax Technologies Corporation (DVAX) Insider Sells 7,500 Shares of Stock
www.americanbankingnews.com - December 15 at 6:32 PM
BidaskClub Downgrades Dynavax Technologies (DVAX) to HoldBidaskClub Downgrades Dynavax Technologies (DVAX) to Hold
www.americanbankingnews.com - December 10 at 3:46 PM
Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - December 5 at 5:16 PM
$37.77 Million in Sales Expected for Dynavax Technologies Corporation (DVAX) This Quarter$37.77 Million in Sales Expected for Dynavax Technologies Corporation (DVAX) This Quarter
www.americanbankingnews.com - December 5 at 9:06 AM
Dynavax Technologies (DVAX) Downgraded to Sell at ValuEngineDynavax Technologies (DVAX) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - December 3 at 3:46 PM
Zacks: Analysts Expect Dynavax Technologies Corporation (DVAX) Will Post Earnings of $0.30 Per ShareZacks: Analysts Expect Dynavax Technologies Corporation (DVAX) Will Post Earnings of $0.30 Per Share
www.americanbankingnews.com - December 3 at 5:36 AM
Dynavax Technologies Corporation (DVAX) Receives Average Rating of "Buy" from BrokeragesDynavax Technologies Corporation (DVAX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 3 at 2:20 AM
Dynavax Technologies CorpDynavax Technologies Corp
www.bloomberg.com - December 2 at 5:09 PM
Dynavax Shares A Glimpse Of The Future - Seeking AlphaDynavax Shares A Glimpse Of The Future - Seeking Alpha
seekingalpha.com - December 2 at 9:49 AM
Report: Exploring Fundamental Drivers Behind Starbucks, Home Depot, Kroger, Dynavax Technologies, Kratos Defense & Security Solutions, and Medtronic — New Horizons, Emerging Trends, and Upcoming DevelopmentsReport: Exploring Fundamental Drivers Behind Starbucks, Home Depot, Kroger, Dynavax Technologies, Kratos Defense & Security Solutions, and Medtronic — New Horizons, Emerging Trends, and Upcoming Developments
finance.yahoo.com - November 28 at 8:46 AM
Dynavax to Present at the Evercore ISI Biopharma Catalyst/Deep Dive ConferenceDynavax to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
finance.yahoo.com - November 27 at 6:00 PM
Dynavax: Now The Fun Begins - Seeking AlphaDynavax: Now The Fun Begins - Seeking Alpha
seekingalpha.com - November 22 at 6:50 PM
Technical Snapshots for These Biotech Stocks -- Dynavax Technologies, Keryx Biopharma, Moleculin Biotech, and TG TherapeuticsTechnical Snapshots for These Biotech Stocks -- Dynavax Technologies, Keryx Biopharma, Moleculin Biotech, and TG Therapeutics
www.bizjournals.com - November 17 at 12:51 PM
Equities Analysts Issue Forecasts for Dynavax Technologies Corporations FY2017 Earnings (DVAX)Equities Analysts Issue Forecasts for Dynavax Technologies Corporation's FY2017 Earnings (DVAX)
www.americanbankingnews.com - November 15 at 6:58 AM
Dynavax Stock Under Selling Pressure (NASDAQ:DVAX) | Benzinga - BenzingaDynavax Stock Under Selling Pressure (NASDAQ:DVAX) | Benzinga - Benzinga
www.benzinga.com - November 15 at 4:33 AM
Dynavax Technologies Corporation (DVAX) Expected to Announce Earnings of $0.30 Per ShareDynavax Technologies Corporation (DVAX) Expected to Announce Earnings of $0.30 Per Share
www.americanbankingnews.com - November 14 at 7:08 PM
Dynavax: Heplisav-B Approved, What Was Said On The Conference Call And What It Means - Seeking AlphaDynavax: Heplisav-B Approved, What Was Said On The Conference Call And What It Means - Seeking Alpha
seekingalpha.com - November 13 at 6:41 PM
Cowen Anticipates Dynavax’s Now-Approved Heplisav Will Lead the HBV Vaccine MarketCowen Anticipates Dynavax’s Now-Approved Heplisav Will Lead the HBV Vaccine Market
finance.yahoo.com - November 13 at 11:49 AM
Today’s Research Reports on Stocks to Watch: Dynavax Technologies and Puma BiotechnologyToday’s Research Reports on Stocks to Watch: Dynavax Technologies and Puma Biotechnology
finance.yahoo.com - November 13 at 11:49 AM
Dynavax stock surges 18% on hepatitis B vaccine approval - MarketWatchDynavax stock surges 18% on hepatitis B vaccine approval - MarketWatch
www.marketwatch.com - November 12 at 5:46 PM
Its Not Too Late to Buy Dynavax Stock After Its Hepatitis B Vaccine Approval - Motley FoolIt's Not Too Late to Buy Dynavax Stock After Its Hepatitis B Vaccine Approval - Motley Fool
www.fool.com - November 11 at 10:58 PM
At Long Last, Dynavax Wins FDA Approval For HeplisavAt Long Last, Dynavax Wins FDA Approval For Heplisav
finance.yahoo.com - November 11 at 5:57 PM
Dynavax Triumphs With Heplisav-B: Now What? - Seeking AlphaDynavax Triumphs With Heplisav-B: Now What? - Seeking Alpha
seekingalpha.com - November 10 at 6:35 PM
Dynavax Stock Climbs On HEPLISAV-Bs Approval By FDA For Hepatitis B In AdultsDynavax Stock Climbs On HEPLISAV-B's Approval By FDA For Hepatitis B In Adults
www.nasdaq.com - November 10 at 11:09 AM

SEC Filings

Dynavax Technologies (NASDAQ:DVAX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Dynavax Technologies (NASDAQ:DVAX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Dynavax Technologies (NASDAQ DVAX) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.